B

Bimeda

Develops medicines and vaccines for animals

Technical Specialist

Full-Time
CA$60k - CA$70k/yr
Senior
Bachelor's
Cambridge, ON, Canada
In Person
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • At least 5 years of related experience.
  • Sterile manufacturing or fill-finish experience in the pharmaceutical or biotech industry is required; sterile injectables experience is preferred.
  • Operational knowledge of sterile and non-sterile products and their manufacturing processes.
  • A university or college degree in an Engineering or Science-related discipline is preferred.
  • Advanced knowledge of the operational principles of pharmaceutical manufacturing equipment and processes for liquid filling, especially sterile parenteral products.
  • Strong knowledge of project management methodologies and industry best practices.
  • Expert computer skills across Microsoft Office, including Word, Excel, PowerPoint, Project, and Outlook.
  • Ability to write and review scientific documents and reports.
  • Ability to complete project assignments independently with strong time management, escalating for clarification or decisions as needed.
  • Conflict resolution skills.
  • Interpersonal savvy and relationship management/networking skills, including across sites and geographies.
  • Strong written and oral communication skills in English.
  • Working knowledge of, or willingness to develop proficiency in, electronic quality management systems and statistical/trending software.
  • Ability to identify needed information, investigate it through multiple sources, analyze problems systematically, interpret information, identify patterns and trends, and deduce cause and effect.
  • Ability to ensure work and information are complete and accurate, prepare carefully for meetings and presentations, and follow up to ensure agreements and commitments are fulfilled.
  • Ability to identify, analyze, and improve existing processes to optimize performance.
  • Ability to communicate clearly and efficiently, listen actively, facilitate information-sharing, confirm understanding, communicate using data and facts, and write clearly in business contexts.
  • Initiative in identifying and completing work before being asked or before the situation requires it.
  • Ability to remain effective amid shifting priorities, new systems, and organizational growth, and help others navigate change.
  • Comfort working within electronic quality and manufacturing systems and using data trending and analytics to support decisions.
  • Ability to maintain a strong safety culture, follow established safe work practices and company/operational procedures, and understand and apply environmental, health, and safety requirements.
  • Ability to adhere to compliance programs, company policies, and procedures.
Responsibilities
  • Support the Cambridge site's strategic projects and initiatives, including line transfers, batch scale changes, new product introductions, contract manufacturing organization technical transfer packages, and post-launch investigations.
  • Support procedural and master batch record updates affecting critical processing parameters.
  • Support research and development technical transfer projects, connecting laboratory development with technical transfer.
  • Support cross-site knowledge transfer and standardization of processes, documentation, and lessons learned across the global manufacturing network.
  • Contribute to digital and data-driven quality initiatives, including the transition from paper-based to electronic quality and manufacturing systems, and data trending and analytics.
  • Provide project support for documentation, process updates, yield-improvement and batch-scale-change data analysis, technical engineering projects, technical transfers, post-commercial remediation, and continuous improvement across the site and wider manufacturing network.
  • Consult vendors, equipment suppliers, clients, third-party consultants, contractors, and other stakeholders to understand user requirements and incorporate them into equipment, process, and facility design for assigned projects.
  • Research and develop requirements for assigned projects by engaging key stakeholders, proposing and justifying approaches, and project-managing solutions to cost, quality, compliance, safety, and delivery targets.
  • Incorporate regulatory requirements accurately into written documents and brief stakeholders and senior management on their implications for projects and timelines.
  • Prepare accurate project progress reports for audiences across the organization.
  • Use statistical tools to analyze process data from investigational trials, commercial manufacturing batches, and Design of Experiments.
  • Lead the post-launch critical product investigation process end-to-end within business timelines.
  • Support operations in resolving Environmental Excursion investigations and identify opportunities to improve processes and prevent recurrence.
  • Drive cross-functional teams to complete critical project activities, provide technical leadership to operations, and oversee installation, operational, and performance qualification activities as required.
  • Deliver required updates to standard operating procedures, master batch records, deviations, and specifications for assigned projects and investigations, and facilitate related training.
  • Organize, chair, and report on meetings to resolve technical and operational issues within the role's scope.
  • Build trust-based relationships with employees, business partners, and leadership through open, two-way communication, and continue developing personal leadership capability.
  • Perform other relevant duties assigned that are commensurate with the role's grading.
Desired Qualifications
  • Sterile injectables experience.
  • Lean/Six Sigma or equivalent continuous-improvement training.

About the company

Bimeda develops and manufactures veterinary medicines and vaccines for veterinarians, farmers and animal health distributors around the world. Its portfolio covers parasite control and infections, alongside pain relief, reproductive health and nutritional supplements for livestock, horses and companion animals. The company makes injections, oral pastes, powders and tablets in its own plants, with formulations and approved uses tailored to each market. It earns revenue by selling Bimeda-branded products and by manufacturing private-label medicines for other animal health companies. Founded in Ireland in 1960, Bimeda has its global headquarters in Dublin, Ireland.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

1960

Get referred to Bimeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Bimeda gained U.S. equine market access: its first approved GastroGard generic launched nationwide in May 2026.
  • U.S. capacity broadens: by May 2026, Bimeda had bought selected manufacturing assets at Dechra's Pomona facility.
  • Bimeda advertises development support in the UK: education funding accompanies 24 starting annual-leave days plus public holidays.

What critics are saying

  • Bimeda's screwworm indication is temporary: its August 2026 Bimectin authorization ends with the emergency declaration or revocation.
  • Bimeda faces an older ulcer brand: FDA's April 2026 review names GastroGard, approved in 1999, as Gastrobim's reference.
  • Factory schedules include nights: Bimeda's September 2026 Le Sueur technician posting lists 9pm-5:30am shifts at $24/hour.

What makes Bimeda unique

  • Bimeda's cattle supplements use dissolving glass: Cosecure releases minerals steadily for up to six months.
  • Bimeda's fish health division designs vaccination plans: AquaTactics combines veterinary consultation with pathology and custom prescription vaccination protocols.
  • Bimeda's laboratory business serves other drugmakers: its Rainbowlabs joint venture tests batches and audits manufacturing quality.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Life Insurance
  • Employee Assistance Program
  • Paid Holidays

Company News

British Veterinary Association
Aug 4th, 2026
New treatment for bovine endometritis.

New treatment for bovine endometritis. 4 Aug 2026 11:00 AM Bimeda UK has launched Bimacure, which it says is the UK's first generic intrauterine cefapirin suspension for cattle, for the treatment of subacute and chronic endometritis. The formulation contains 500mg cefapirin per syringe and is for use in cows at least 14 days after parturition. It is supplied in packs of 10 sets each of syringes, administration catheters and gloves; the catheter and syringe connection have been designed to avoid 'pop offs' at critical moments. The firm says feedback about the product from other markets has been "extremely positive".

Feedstuffs
May 19th, 2026
Bimeda introduces enhanced BOVitalize Plus.

Bimeda introduces enhanced BOVitalize Plus. Product now fortified with A. oryzae to support cattle health, digestion and performance. May 19, 2026 Bimeda is proud to announce the launch of its newly enhanced BOVitalize Plus, now fortified with Aspergillus oryzae to deliver an even more comprehensive approach to cattle health, digestion and performance. This advancement builds on the trusted formulation of essential trace minerals and vitamins - selenium, copper, zinc, vitamin A and vitamin E - by adding targeted digestive support designed to help cattle get more from every bite of feed. For producers and veterinarians, the inclusion of A. oryzae represents a significant step forward in rumen efficiency. A oryzae provides enzymatic activity that enhances fiber breakdown, helping cattle maintain intake and digestive consistency during diet transitions, periods of stress or when forage quality declines. By supporting more efficient fiber utilization, the upgraded BOVitalize Plus helps optimize nutrient absorption, stabilize the rumen environment, and promote improved overall performance across all stages of production. This enhancement reflects its commitment to delivering solutions that truly support the challenges cattle face every day," said Dr. Eric Moore, head of technical services North America at Bimeda. "By combining key vitamins and minerals with the proven digestive benefits of Aspergillus oryzae - and refining how the formula performs in suspension - we're offering a more complete, performance-driven supplement designed to keep animals healthy, efficient and moving forward." The improved BOVitalize Plus continues to offer the same convenient oral dosing, eliminating the need for additional injections and reducing labor at the chute. With the added digestive benefits of A. oryzae, the product now delivers an even stronger value proposition for both cow-calf and stocker operations seeking to improve health, consistency and overall productivity. BOVitalize Plus is now available through authorized Bimeda distributors. Bimeda is a leading global manufacturer of animal health products used in more than 80 countries worldwide and is committed to providing innovative solutions that support livestock health, welfare and performance. Feedstuffs is the news source for animal agriculture

The Horse
May 6th, 2026
Bimeda(r) announces U.S. Availability of gastrobim(tm)(omeprazole) the first and only fda-approved bioequivalent to gastrogard(r)(omeprazole) for Equine Gastric Ulcer treatment.

Bimeda(r) announces U.S. Availability of gastrobim(tm)(omeprazole) the first and only fda-approved bioequivalent to gastrogard(r)(omeprazole) for Equine Gastric Ulcer treatment. Now available nationwide. Horse owners are encouraged to contact their veterinarian. Bimeda(R), a global leader in animal health solutions, today announced the U.S. launch of GASTROBIM(TM)(omeprazole), the first and only FDA-approved bioequivalent to GastroGard(R)(omeprazole) for the treatment and prevention of recurrence of gastric ulcers in horses and foals four weeks of age and older. This apple-flavored formulation offers veterinarians, trainers, and horse owners a clinically equivalent, high-quality alternative for the effective management of Equine Gastric Ulcer Syndrome (EGUS), addressing a critical need in equine health. Since its initial launch in 2024, GASTROBIM(TM) has rapidly emerged as the fastest-growing omeprazole product in Canada and Europe. Its strong adoption and positive reception among veterinarians and horse owners underscore its proven efficacy in treating and healing gastric ulcers, reinforcing its position as a trusted therapeutic option worldwide. The introduction of GASTROBIM(TM) in the U.S. further expands Bimeda's established equine portfolio, which includes leading brands such as EquiMAX(R)(1.87% ivermectin 14.03% praziquantel), Polyglycan(TM)(hyaluronic acid + chondroitin sulfates C4 & C6 + N-acetyl-D-glucosamine sterile solution), Detomequin(R)(detomidine hydrochloride), and Bimectin(R)(ivermectin paste), and reflects the company's ongoing commitment to delivering innovative, reliable solutions to the equine industry. "We are thrilled to introduce GASTROBIM(TM) to the U.S. market," said Eric Moore, DVM, Bimeda's Head of Technical Services North America. "Gastric ulcers remain one of the most common and performance limiting conditions in horses. Offering a bioequivalent, rigorously tested treatment underscores our commitment to supporting equine health, welfare, and performance at an affordable price." Equine Gastric Ulcer Syndrome (EGUS) affects a significant percentage of performance horses, often leading to reduced appetite, behavioral changes, discomfort, and decreased athletic performance. By introducing a bioequivalent, apple-flavored alternative, Bimeda aims to broaden access to effective treatment options and support improved health and performance outcomes across the equine industry.

American Association of Swine Veterinarians
Apr 15th, 2026
People on the move: dr. Chris Olsen.

People on the move: dr. Chris Olsen. Dr. Chris Olsen has joined Bimeda as their U.S. Swine Technical Service Veterinarian. In this role, he will support the growth of the company's swine autogenous vaccine business and provide technical expertise across its swine pharmaceutical portfolio. He was previously employed by Pharmacosmos. Dr. Olsen's updated contact information is available at aasv.org/directory. Are you on the move? Let Aasv Go know at [email protected].